BAX Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Filed Against Baxter International, Inc.

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][2]. Allegations - The complaint alleges that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple malfunctions, injuries, and deaths related to the Novum LVP but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVP were claimed to be materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, that Baxter would suspend all new Novum LVP sales, the company's stock price dropped by 22.4%, closing at $21.76 [3]. Next Steps for Shareholders - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by December 15, 2025 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Company Background - Robbins LLP, the firm handling the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].